[Kidney retransplantation: indications and limits].
Whether or not to consider a uremic patient for retransplantation remains a matter of debate. Donor shortage and putative poor outcomes are the main cons, improved results in the last decade and a better survival (HR 0.50) with retransplantation than dialysis stand as pros. The percentage of patients waitlisted for retransplantation or already having been retransplanted is increasing (up to 20-30%) and the absolute contraindications are limited to rare conditions (loss of previous transplant due to anti-glomerular basement antibodies in Alport's syndrome, early recurrence of GNF or hemolytic uremic syndrome). When retransplantation is considered, however, careful screening for risk factors is mandatory, whether they are related to the previous graft or to the recipient's clinical features or the donor's demographics and immunological status. In the last decade the clinical outcomes of retransplantation have significantly improved. No difference in patient survival at the fifth year has been reported between first, second and third grafts. The kidney survival at the same interval is above 70% for the second graft and 65% for the third graft. Nephrectomy of a previous graft is not necessary if not for clinical reasons. As far as the maximum number of retransplants is concerned, most transplant centers (69%) set no clear-cut limit. In conclusion, also taking into account that many patients after graft failure ask for readmission to the waiting list (75% in our experience), we think the retransplantation option should always be evaluated.
Segoloni
G P
GP
S.C. Nefrologia Dialisi e Trapianto U, Azienda Ospedaliera Universitaria, S. Giovanni di Torino, Cattedra di Nefrologia dell'Università degli Studi, Torino. giuseppe.segoloni@unito.it
Messina
M
M
Basso
E
E
Quercia
A
A
Fop
F
F
D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality; D011379:Prognosis; D012086:Reoperation; D015996:Survival Rate; D016896:Treatment Outcome